ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1265

External Validation of a Giant Cell Arteritis Probability Score (GCAPS) to Risk Stratify GCA Referrals: Experience from a United Kingdom Fast Track Clinic

Edward Appleby1 and Qasim Akram2, 1Stockport NHS Foundation Trust, Altrincham, United Kingdom, 2NHS- Stockport, Manchester, United Kingdom

Meeting: ACR Convergence 2022

Keywords: classification criteria, giant cell arteritis, Ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Imaging of Rheumatic Diseases Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Giant Cell Arteritis (GCA) is the most common large vessel vasculitis which can result in irreversible blindness if not diagnosed and treated promptly. We run a consultant led Fast Track GCA clinic (FTC) to ensure a rapid assessment and treatment of patients with GCA.

A GCA pre-test probability score is important to prioritise referrals, ensure patients are triaged safely, prevent unnecessary burden of steroid treatment on patients and reduce service pressures.

The aims of our study are to externally validate the use of the Southend GCA probability score (SGCAPS) in our FTC which covers the Stockport and Cheshire region of Greater Manchester, UK. The SGCAPS was developed in 2019 by Laskou et al and then subsequently shown to successfully risk stratify patients referred to the Southend FTC by Sebastian et al in 2020.

Methods: SGCAPS data was collected prospectively in patients who presented to the Stockport FTC over an 18-month period between April 2020 and September 2021. GCA diagnoses were supported by US of the temporal arteries and axillary arteries with or without temporal artery biopsy and confirmed at 6 months by the responsible clinician. Other additional tests that were used included PET-CT. We applied the SGCAPS score to all patients and risk stratified into three groups: low-probability (LP) (score < 9), intermediate-probability (IP) (score 9-12) and high-probability (HP) (score >12). We assessed the number of GCA cases in each group.

Results: A total of 101 patients were referred to the FTC for suspected GCA during the specified time period. There was a female to male ratio 1.8:1. Mean age 70.6 years old. 33 (32.7%) patients had a confirmed diagnosis of GCA. 58 (57.4%%) patients were divided into the LP group, 31 (30.7%) in the IP group and 12 (%) in the HP group. 1 (1.72%) patient in the LP group, 20 (60.4%) in the IP group and 12 (100%) in the HP group had a diagnosis of GCA. The LP group (GCAPS< 9) had a sensitivity of 96.9% and a specificity of 83.8% for the diagnosis of GCA. The HP group ( >12) had a sensitivity of 36.37% but a specificity of 100% for a diagnosis of GCA. The single patient in the LP group with a diagnosis of GCA had a GCAPS score of 8, as such a score of ≥8 can be used with 100% sensitivity for the diagnosis of GCA (specificity 73.9%). Ultrasound scanning had a sensitivity of 73.4% and a specificity of 96.9% for diagnosis of GCA.

Conclusion: This study supports the use of SGCAPS to risk stratify patients referred to a FTC. The high sensitivity of this test in the LP group means that the SGCAPS can be safely used to rule out GCA at a score < 8. Furthermore, the high specificity of this test in the HP group means that SGCAPS could be used to rule in GCA at score of >12.

Using the SGCAPS < 8 to rule out GCA we could potentially reduce the number of urgent GCA referrals by approximately 50%. Additionally, by not requesting temporal artery ultrasound scans in low-probability patients, we can reduce the number of temporal artery ultrasound scans by 50%. The clinical need for referral and scanning certainly remains important in the intermediate-probability group. Despite the possibility to rule in GCA in patients with a score >12 with 100% specificity, referral and scanning will remain an important part of the best practice management in GCA patients.


Disclosures: E. Appleby, None; Q. Akram, None.

To cite this abstract in AMA style:

Appleby E, Akram Q. External Validation of a Giant Cell Arteritis Probability Score (GCAPS) to Risk Stratify GCA Referrals: Experience from a United Kingdom Fast Track Clinic [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/external-validation-of-a-giant-cell-arteritis-probability-score-gcaps-to-risk-stratify-gca-referrals-experience-from-a-united-kingdom-fast-track-clinic/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/external-validation-of-a-giant-cell-arteritis-probability-score-gcaps-to-risk-stratify-gca-referrals-experience-from-a-united-kingdom-fast-track-clinic/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology